Application

This Anti-Amyloid Antibody, β 1-40 is validated for use in ELISA, IH, WB for the detection of Amyloid.

Research Sub CategoryNeurodegenerative Diseases

Research CategoryNeuroscience

Western blot: 1-10 µg/mL (Chemiluminescence technique)

Immunohistochemistry: 10-50 µg/mL using formalin or paraformaldehyde fixed Alzheimer′s brain tissue.

ELISA: 1:10,000-1:100,000 (50-100 ng immunogen peptide/well)

Optimal working dilutions must be determined by the end user.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

The cerebral and vascular plaques associated with Alzheimer′s disease (AD) are mainly composed of amyloid beta peptides (Ab). Ab is derived from cleavage of the amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. Ab [1-40], Ab [1-42], and Ab [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last APP processing step. Ab [1-40], [1-42] and [1-43] peptides are major constituents of the plaques and tangles that occur in AD. Ab antibodies and peptides have been developed as tools for elucidating the biology of AD.

Immunogen

A 7 amino acid peptide sequence from the C terminus of human beta-amyloid 1-40.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

ImmunoAffinity Purified

Affinity Purified immunoglobulin. Liquid in PBS with 0.1% BSA, no preservative.

Specificity

Recognizes beta-amyloid 1-40. One of the most important and initial steps which causes loss of memory and cognition in Alzheimer′s Disease (AD) involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43 amino acid peptides (beta amyloid 1-40, 1-42 and 1-43). Polymerization of beta-amyloid and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition. The immunogen peptide shows homology with beta-amyloid 1-28 and beta-amyloid 12-28. No cross reactivity is observed with CGRP.

Storage and Stability

Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.